文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

低中危前列腺癌超分割放疗:高剂量率近距离治疗与立体定向消融放疗比较

Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
PubMed 文献 · Radiother Oncol · 2021-02-24

单中心回顾性分析185例低中危前列腺癌患者,比较19 Gy/1次、26 Gy/2次高剂量率近距离治疗(HDR BT)与36.25 Gy/5次立体定向消融放疗(SABR)的生化控制率(BCR)及晚期胃肠(GI)和泌尿生殖(GU)毒性。中位随访60.5个月,26 Gy/2次HDR BT的BCR与36.25 Gy/5次SABR相当且毒性更低;两种方案BCR均优于19 Gy/1次HDR BT。

要点

  • 26 Gy/2次HDR BT的5年BCR达95%,与36.25 Gy/5次SABR的92%相当。
  • 19 Gy/1次HDR BT的5年BCR仅69%,显著低于2次HDR BT和5次SABR。
  • ≥2级GU毒性:19 Gy/1次组30%,显著高于26 Gy/2次组的5%。

核心结论

  • 26 Gy/2次HDR BT与36.25 Gy/5次SABR相比,生化控制率相当且毒性更低。
  • 2次HDR BT和5次SABR的生化控制率均优于单次19 Gy HDR BT。
  • 2次HDR BT方案应作为未来临床试验的重要对照。

研究设计与样本

  • 中位随访60.5个月,生化控制率采用Phoenix定义,毒性按CTCAE v4.0评估。

主要发现

  • 全组3年和5年BCR分别为95%和85%。
  • 19 Gy/1次、26 Gy/2次和36.25 Gy/5次组的5年BCR分别为69%、95%和92%。
  • ≥2级GI事件5年累积发生率在19 Gy/1次、26 Gy/2次和36.25 Gy/5次组分别为0%、2%和4%,5次SABR组显著高于两个HDR BT组(p < 0.05),两个HDR BT组间无显著差异(p = 0.15)。
  • ≥2级GU事件5年累积发生率在19 Gy/1次、26 Gy/2次和36.25 Gy/5次组分别为30%、5%和6%,26 Gy/2次组显著低于19 Gy/1次组(p < 0.05),26 Gy/2次组与36.25 Gy/5次组无显著差异(p = 0.37)。

临床怎么用

  • 对于低中危前列腺癌,26 Gy/2次HDR BT可作为与36.25 Gy/5次SABR等效且毒性更低的超分割方案选择。
  • 应避免采用单次19 Gy HDR BT方案,因其生化控制率较低且≥2级GU毒性较高。

局限性

  • 单中心回顾性研究,样本量185例,可能存在选择偏倚。
  • 中位随访60.5个月,缺乏更长期疗效和毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the biochemical control rates (BCRs), late gastrointestinal (GI) and genitourinary (GU) toxicities in patients with low- and intermediate risk prostate cancer (PCa) treated with high-dose-rate brachytherapy (HDR BT) of 19 Gy/1 fraction, 26 Gy/2 fractions, or stereotactic ablative radiotherapy (SABR) of 36.25 Gy/5 fractions. METHODS AND MATERIALS: Between August 2008 and December 2017, patients with low- and intermediate risk PCa who received single dose or 2-fraction HDR BT, or 5-fraction SABR at a single institution were included. BCR for the whole population and the individual treatment groups were calculated using the Phoenix definition. Post treatment GI and GU toxicities were evaluated according to the CTCAE v4.0 guidelines. RESULTS: 185 patients with low- and intermediate risk PCa were included in this study with a median follow up of 60.5 months. BCRs at 3 and 5 years were 95% and 85% for all patients. The 5-year BCRs were 69%, 95% and 92% for the 19 Gy/1 fraction, 26 Gy/2 fractions and 36.25 Gy/5 fractions groups respectively. The cumulative 5-year incidence rates of ≥grade 2 GI events in the 19 Gy/1fr, 26 Gy/2fr and 36.25 Gy/5fr groups were 0%, 2% and 4%, respectively. Incidence rates in those treated in the 5-fraction SABR arm were significantly higher (p < 0.05) than those treated in both HDR BT arms where no statistically significant difference between the two HDR BT groups was seen (p = 0.15). The cumulative 5-year incidence rates of ≥grade 2 GU events in the 19 Gy/1fr, 26 Gy/2fr and 36.25 Gy/5fr groups were 30%, 5% and 6%, respectively. No statistically significant difference was found between the 26 Gy/2fr and 36.25 Gy/5fr (p = 0.37) treatment arms but the incidence rate in the 26 Gy/2fr were significantly lower than those seen after 19 Gy/1fr (p < 0.05). CONCLUSIONS: 26 Gy/2 fractions HDR BT provided equivalent BCR with lower toxicity compared to 36.25 Gy/5 fractions SABR. Both 2-fraction HBR BT and 5-fraction SABR achieved better BCRs than single dose 19 Gy HDR BT. The two-fraction HDR BT schedule should be considered as an important comparator in future clinical trials.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Tsang YM, Tharmalingam H, Belessiotis-Richards K, et al. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy. Radiother Oncol. 2021. PMID: 33639192. doi:10.1016/j.radonc.2021.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。